scholarly journals Serum Midkine Levels in Systemic Lupus Erythematosus

2018 ◽  
Vol 6 (8) ◽  
pp. 1323-1327 ◽  
Author(s):  
Blondina Marpaung ◽  
Andi Raga Ginting ◽  
OK Moehad Sjah
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Systemic Disease ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Significant Difference ◽  
Healthy Control

BACKGROUND: Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.AIM: The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the relationship between the serum MK level and disease activity in SLE.METHODS: This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 0.05 was considered statistically significant.RESULTS: There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 0.018).CONCLUSION: Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the pathogenesis of SLE.

Evaluation of the Incidence of Discoid Lupus Erythematosus in Patients with Systemic Lupus Erythematosus and Its Relationship to Disease Activity

2014 ◽  
Vol 18 (5) ◽  
pp. 316-319 ◽  
Author(s):  
Massoud Saghafi ◽  
Kamila Hashemzadeh ◽  
Sima Sedighi ◽  
Mohammad Javad Yazdanpanah ◽  
Zahra Rezaieyazdi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Systemic Disease ◽  
Severe Disease ◽  
Discoid Lupus Erythematosus ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Cutaneous Manifestations

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with wide clinical features ranging from cutaneous manifestations to systemic disease. Skin is one of the most commonly affected organs in SLE. Objective: To determine whether there is any correlation between discoid lupus erythematosus (DLE) and the severity of SLE. Methods: In a prospective cross-sectional study, 60 consecutive patients with newly diagnosed SLE were enrolled. Skin biopsy was performed to establish the diagnosis of DLE. Disease activity was determined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). A SLEDAI-2K score ≥ 10 was considered active and severe disease. Results: Eleven SLE patients (9 females and 2 males) had DLE (18.3%) and 49 patients (46 females and 3 males) had SLE without DLE (81.7%). The mean age of patients with DLE was 30.18 ± 11.07 years and in patients without it was 28.4 ± 10.26 years ( p = .6). Three of 11 patients with DLE (27.3%) and 14 of 49 patients without DLE (28.6%) had a SLEDAI-2K score ≥ 10 ( p = 1). Conclusion: The presence of DLE in our patients with SLE was not associated with less severe disease.

scholarly journals Pregnancy outcomes between pregnant systemic lupus erythematosus patients with clinical remission and those with low disease activity: A comparative study

2021 ◽  
Author(s):  
Worawit Louthrenoo ◽  
Thananant Trongkamolthum ◽  
Nuntana Kasitanon ◽  
Antika Wongthanee
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Pregnancy Outcomes ◽  
Clinical Remission ◽  
Activity Index ◽  
Physician Global Assessment ◽  
Systemic Lupus ◽  
Low Disease Activity ◽  
Significant Difference

Objectives: This study aims to compare pregnancy outcomes between systemic lupus erythematosus (SLE) patients who attained clinical remission based on the Definition of Remission in SLE (DORIS) and those with lupus low disease activity based on Low Lupus Disease Activity State (LLDAS). Patients and methods: Between January 1993 and June 2017, a total of 90 pregnancies (one twin pregnancy) from 77 patients (mean age: 6.9±4.8 years; range, 17.9 to 37.3 years) were included in the study. The clinical remission and the LLDAS groups were modified into modified clinical remission and LLDAS groups, respectively by omitting Physician Global Assessment (PGA). The clinical SLE disease activity index (cSLEDAI) score was used for LLDAS. Results: Pregnancies in 49 patients occurred, when they were in modified clinical remission and in 57 in modified LLDAS. There was no significant difference in demographic characteristics, disease activity, or medication received at conception between the two groups. Pregnancy outcomes were similar between the modified clinical remission and the modified LLDAS groups in terms of successful pregnancy (83.67% vs. 84.21%), full-term births (38.78% vs. 38.60%), fetal losses (16.33% vs. 15.79%), spontaneous abortions (14.29% vs. 14.04%), small for gestational age infants (18.37% vs. 19.30%), low birth weight infants (42.86% vs. 40.35%), maternal complications (46.94% vs. 49.12%), and maternal flares (36.73% vs. 40.35%). The agreement of pregnancy outcomes was very high between the two groups (91.11% agreement). Conclusion: Pregnancy outcomes in SLE patients who achieved modified clinical remission and modified LLDAS were comparable.

scholarly journals Prolactin as a marker of active disease in systemic lupus erythematosus

2021 ◽  
Author(s):  
Jorge Medina Castillo ◽  
Nayeli Nicté López Villa
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Serum Prolactin ◽  
Categorical Variables ◽  
Continuous Variables ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Active Disease

Abstract Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI).Methods. In this cross-sectional observational study, serum prolactin, age, sex, treatment, as well as manifestations of active disease were determined. Disease activity was evaluated using the Mexican Systemic Lupus Erythematosus Activity Index (MEX-SLEDAI). The correlation of MEX-SLEDAI with prolactin was determined using the Spearman correlation coefficient. The significance of differences between continuous variables was determined with the non-paired Student’s t test and the significance of differences between categorical variables was determined with Chi-square test.Results. 55 patients were included, 10 (18.1%) had MEX-SLEDAI ≥ 7 and 45 (81.8%) less than 7. A positive correlation was found with a Spearman rho 0.387 (p = 0.004) between the MEX-SLEDAI and the levels serum prolactin. Subjects with active disease and hyperprolactinemia had 80% manifestations at the renal level (p = 0.001).Conclusion. There is significant correlation between prolactin levels and disease activity. Hyperprolactinemia were detected in patients with renal activity as well as those with MEX-SLEDAI ≥ 7.

Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus

Lupus ◽  
2018 ◽  
Vol 28 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Z Li ◽  
J Xiao ◽  
H Song ◽  
Q Chen ◽  
H Han ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Maximum Amplitude ◽  
Disease Activity Index ◽  
Systemic Lupus ◽  
Significant Difference ◽  
Coagulation Status ◽  
Α Angle

Background The coagulation status of patients with systemic lupus erythematosus (SLE) is quite complicated, and there are currently no simple efficient methods for its evaluation. We explored the feasibility of thromboelastography (TEG) for this purpose. Methods Paediatric SLE patients were divided into different groups based on Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. TEG parameters were compared between patients and healthy controls (HCs) and in patients by level of disease activity. Six patients treated with pulse methylprednisolone were also analysed before and after treatment. Results Thirty-nine children with SLE were enrolled, one of whom had bleeding and three of whom had thrombosis. The four TEG tracings of these four children were different. The TEG parameters of the patients (except the four children mentioned above) showed hypercoagulability, shortened R and K times, increased α-angle and maximum amplitude (MA), decreased LY30 and increased clot index (CI) compared with the parameters of the HCs ( P < 0.05). With respect to disease activity, patients with higher SLEDAI scores showed more obvious hypercoagulability with shortened R and K times and increased α-angle and CI ( P < 0.05). Furthermore, there was a negative correlation between both the R time and K time and SLEDAI scores ( r = –0.435, P < 0.01 and r  =  –0.572, P  < 0.001, respectively) and a positive correlation between both α-angle and CI and SLEDAI scores ( r = 0.581, P  < 0.001 and r  =  0.544, P  < 0.01, respectively). No significant difference in coagulation status was found between pre- and post-pulse therapy. Conclusions Compared with the HCs, paediatric SLE patients showed hypercoagulability caused by increased coagulation and decreased fibrinolysis. These coagulation changes were associated with disease activity. TEG could be a potential tool for evaluating the coagulation status of children with SLE.

Vitamin D in Colombian patients with systemic lupus erythematosus and its correlation with disease activity

Lupus ◽  
2020 ◽  
Vol 29 (10) ◽  
pp. 1297-1304 ◽  
Author(s):  
Andrés F Cardona-Cardona ◽  
Jairo A Cerón y Cerón
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Activity Index ◽  
Inverse Correlation ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Low Levels

Introduction Patients with systemic lupus erythematosus (SLE) frequently present low levels of vitamin D. However, studies that have evaluated its association with disease activity have generated contradictory results. Methods A cross-sectional study was carried out on patients diagnosed with SLE in two hospitals in Manizales, Colombia. Disease activity was evaluated by the SLE disease activity index 2000 (SLEDAI-2K) and serum concentration of 25-hydroxyvitamin D (25(OH)D) was measured by chemiluminescence. The correlation analysis was accomplished with the Spearman correlation coefficient. Results The study included 51 patients. The median SLEDAI-2K score was 8 points. The mean serum level of 25(OH)D was 24.5 ng/ml. Of the participants, 37.3% had vitamin D insufficiency and 35.3% had deficiency. An inverse correlation was found between the levels of the 25(OH)D and the SLEDAI-2K score ( r = –0.578, p < 0.001), being greater in late-onset lupus, with absence of polyautoimmunity and in patients using glucocorticoids. Conclusions Low levels of vitamin D are frequent in SLE, presenting an inverse correlation with the disease activity. This is influenced by the use of glucocorticoids, the presence of late-onset lupus and the absence of polyautoimmunity.

scholarly journals Vitamin D Deficiency in Egyptian Systemic Lupus Erythematosus Patients: How Prevalent and Does it Impact Disease Activity?

2016 ◽  
Vol 11 ◽  
pp. IMI.S40035 ◽  
Author(s):  
Nouran M. Abaza ◽  
Reem M. El-Mallah ◽  
Asmaa Shaaban ◽  
Sameh A. Mobasher ◽  
Khaled F. Al-hassanein ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Disease Activity ◽  
Vitamin D Deficiency ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Damage Index ◽  
Systemic Lupus ◽  
Vitamin D Levels ◽  
Significant Difference

Background The emerging role of vitamin D in immunology and autoimmune disorders has been a worldwide interest in the last decade. Systemic lupus erythematosus (SLE) patients are particularly at a delicate position predisposing them to suffer from vitamin D deficiency due to the multiple risk factors accompanying the disease. Whether vitamin D deficiency is also involved as a risk factor for developing SLE and affecting its course is a considerable concern. Objectives The objective of this study was to estimate the prevalence of vitamin D deficiency in SLE patients and its relation to disease. MATERIALS AND METHODS: In our observational cross-sectional study, serum levels of vitamin D [25(OH)D] in 60 SLE patients and 30 age- and sex-matched healthy controls were assessed and estimated for deficiency and insufficiency at 10 and 30 ng/mL, respectively. Disease activity was evaluated by SLE disease activity index (SLEDAI), irreversible organ damage by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI), and severity by Severity of Disease Index. Fatigue was measured by visual analog scale. Results Significantly lower levels of 25(OH)D were found in SLE patients (17.6 ± 6.9 ng/mL) in comparison to controls (79.0 ± 28.7 ng/mL), with a statistically high significant difference ( t = -11.2, P < 0.001). High prevalence of vitamin D insufficiency and deficiency was detected as 73.3% and 23.3%, respectively. Vitamin D had a highly significant negative correlation with SLEDAI ( r = -0.495, P < 0.001), SLICC ( r = -0.431, P < 0.05), and fatigue ( r = -0.436, P < 0.05). Conclusion Vitamin D deficiency and insufficiency were found to be prevalent in SLE patients in our study and related to disease activity and fatigue. If needed, routine screening and consequent repletion of vitamin D are recommended in SLE patients. Restoring adequate vitamin D levels in SLE patients should be more explored as a potential yet simple measure to their usual management to improve their condition.

scholarly journals Serum Complement Protein C3a Level is Associated With Anti dsDNA Ab in Systemic Lupus Erythematosus: a Brief Report

2021 ◽  
Author(s):  
Yao-Hua Cai ◽  
Jun Deng ◽  
Zhao-Lin Chen ◽  
Heng Mei ◽  
Liang Tang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Complement Protein ◽  
Systemic Lupus ◽  
Laboratory Procedure ◽  
Autoantibody Production ◽  
Wide Range ◽  
Significant Difference

Abstract Objective. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by complement dysfunction and a wide range of autoantibody production. However, data about the relation between C3a and anti-ds DNA Ab in SLE are scarce. Methods.Thirteen SLE patients, diagnosed on the basis of SLICC classification criteria (6 patients positive for anti-Sm Ab, 7 patients positive for anti-dsDNA Ab) were enrolled in the present study. Serum levels of C3a, C1q were quantified by Western Blotting. Clinical, biochemical, serological and other markers of disease activity (anti-SM, anti-dsDNA) were measured by standard laboratory procedure.Results.Serum C3a levels were significantly higher in anti-dsDNA Ab (+) patients compared to anti-Sm Ab (+) patients (p < 0.01). And serum C3a levels positively correlated with SLE Disease Activity Index (SLEDAI) (p < 0.05, r = 0.6134). Interestingly, C3a was slightly correlated positively with D-Dimer, but no significant difference was found (p = 0.0983, r = 0.4783).Conclusion.C3a level is relative to SLE disease activity and may be a promising biomarker for monitoring thrombophilia in SLE.

Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity

Lupus ◽  
2018 ◽  
Vol 27 (8) ◽  
pp. 1287-1295 ◽  
Author(s):  
W D Abdul Kadir ◽  
A Jamil ◽  
S Sazliyana Shaharir ◽  
N Md Nor ◽  
A H Abdul Gafor
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Damage Index ◽  
Disease Activity Index ◽  
Sun Exposure ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Sun Avoidance

Objective The objective of this paper is to determine photoprotection awareness, knowledge, practices, and its relationship with disease activity and damage in patients with systemic lupus erythematosus (SLE). Methods A cross-sectional study was performed. Data were acquired from in-person interviews and medical records. Results A total of 199 (89.6%) females and 23 (10.4%) males were recruited. Median age was 39.00 (interquartile range (IQR) 18) years, disease duration 12.12 (IQR 8) years, Fitzpatrick skin phototype III 119 (53.6%) and IV 81 (36.5%). Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) was 2.95 (IQR 4) while Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC-ACR DI) was 1.20 (IQR 2). The majority 205 (92.3%) were aware of sun exposure effects on SLE. Photoprotection methods were shade seeking 209 (94.1%), sun avoidance 212 (95.5%), long pants 168 (75.7%), long sleeves 155 (69.8%), sunscreen 116 (52.3%), sunglasses 114 (51.4%) and head cover 103 (46.4%). Significantly higher photoprotection practice scores (PPS) were observed in females, Malays, and individuals with higher education level and internet accessibility. PPS were not significantly correlated with SLICC-ACR DI and SLEDAI-2 K. Independent predictors for good photoprotection practice (GPP) were ethnicity (OR = 3.66, 95% CI 1.78–7.53), awareness (OR = 3.77, 95% CI 1.09–13.08) and cutaneous involvement (OR = 2.43, 95% CI 1.11–5.28). Photoprotection methods and GPP were not predictors for disease activity or damage. Conclusion Photoprotection awareness and knowledge was good. Shade seeking and sun avoidance were the common photoprotection methods practised. The use of sunscreen requires improvement. Photoprotection awareness and cutaneous manifestation were predictors for GPP. Neither photoprotection methods nor GPP were associated with disease activity or damage.

Circulating antioxidant levels in systemic lupus erythematosus patients: a systematic review and meta-analysis

2019 ◽  
Vol 13 (13) ◽  
pp. 1137-1152 ◽  
Author(s):  
Napoleon Bellua Sam ◽  
Bao-Zhu Li ◽  
Rui-Xue Leng ◽  
Hai-Feng Pan ◽  
Dong-Qing Ye
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Precise Estimation ◽  
Significant Difference

Aim: To derive a precise estimation on plasma/serum level of SOD, GPx, CAT and GSH levels in systemic lupus erythematosus (SLE) patients. Methods: A total of 36 articles from electronic databases were finally included with 1120 SLE patients and 1024 healthy controls considered for antioxidant levels. Results: The levels of CAT and GSH were significantly lower, while SOD and GPx levels were slightly lower in patients with SLE compared with healthy controls. Subgroup analysis indicated that Arabs, ages ≥40 and SLE diseases activity index <6 had a significant association of SOD and CAT levels with SLE patients. Conclusion: The results demonstrated a significant lower CAT and GSH levels and also revealed no significant difference for SOD and GPx levels in SLE patients.

Interleukin-34 and Disease Activity in Systemic Lupus Erythematosus Patients

2021 ◽  
Vol 27 (2) ◽  
pp. 196
Author(s):  
Rizki Luly Ya Fatwa Pulungan ◽  
Ratna Akbari Ganie ◽  
Zuhrial Zubir
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Enzyme Linked Immunosorbent Assay ◽  
Close Monitoring ◽  
Systemic Lupus Erythematosus Disease ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Sledai Score

Systemic Lupus Erythematosus (SLE) is characterized by exacerbation and remission, which needs close monitoring ofthe disease activity. Systemic lupus erythematosus disease activity can be determined by the SLE Disease Activity Index(SLEDAI) score. Evaluation of the disease activity is essential to be a guidance for treatment. Interleukin-34 (IL-34) is relatedto the pathogenesis of SLE. Serum IL-34 can be a candidate marker to evaluate SLE disease activity, and it is correlated withthe SLEDAI score. This study aimed to determine the correlation between IL-34 level and disease activity in SLE patientsbased on the SLEDAI (Mex-SLEDAI) score. An observational analytical study with a cross-sectional design was carried out insix months (June-November 2019) in 27 SLE patients in the Department of Internal Medicine, Faculty of Medicine, SumateraUtara University/Adam Malik General Hospital, Medan. Systemic lupus erythematosus disease activity was measured basedon the Mex-SLEDAI score. Serum and urine were collected to obtain the Mex-SLEDAI score and IL-34 level. IL-34 level wasmeasured in all subjects by using Enzyme-Linked Immunosorbent Assay (ELISA). Spearman correlation test was used todetermine the correlation between IL-34 level and disease activity in SLE patients based on the SLEDAI (Mex-SLEDAI) score.There was a significant correlation between IL-34 level and disease activity in SLE patients based on SLEDAI (Mex-SLEDAI)score (r=0.965, p < 0.001). Further studies were needed with a sample of SLE patients in a balanced proportion based ontheir disease activity to obtain representative IL-34 levels in SLE patients based on their disease activity.

Sign in / Sign up

Export Citation Format

Share Document